Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity
The origins of preexisting SARS-CoV-2 cross-reactive antibodies and their potential impacts on vaccine efficacy have not been fully clarified. In this study, we demonstrated that S2 was the prevailing target of the preexisting S protein cross-reactive antibodies in both healthy human and SPF mice. A...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2117503 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850140144480288768 |
|---|---|
| author | Liqiu Jia Shufeng Weng Jing Wu Xiangxiang Tian Yifan Zhang Xuyang Wang Jing Wang Dongmei Yan Wanhai Wang Fang Fang Zhaoqin Zhu Chao Qiu Wenhong Zhang Ying Xu Yanmin Wan |
| author_facet | Liqiu Jia Shufeng Weng Jing Wu Xiangxiang Tian Yifan Zhang Xuyang Wang Jing Wang Dongmei Yan Wanhai Wang Fang Fang Zhaoqin Zhu Chao Qiu Wenhong Zhang Ying Xu Yanmin Wan |
| author_sort | Liqiu Jia |
| collection | DOAJ |
| description | The origins of preexisting SARS-CoV-2 cross-reactive antibodies and their potential impacts on vaccine efficacy have not been fully clarified. In this study, we demonstrated that S2 was the prevailing target of the preexisting S protein cross-reactive antibodies in both healthy human and SPF mice. A dominant antibody epitope was identified on the connector domain of S2 (1147-SFKEELDKYFKNHT-1160, P144), which could be recognized by preexisting antibodies in both human and mouse. Through metagenomic sequencing and fecal bacteria transplant, we demonstrated that the generation of S2 cross-reactive antibodies was associated with commensal gut bacteria. Furthermore, six P144 reactive monoclonal antibodies were isolated from naïve SPF mice and were proven to cross-react with commensal gut bacteria collected from both human and mouse. A variety of cross-reactive microbial proteins were identified using LC-MS, of which E. coli derived HSP60 and HSP70 proteins were confirmed to be able to bind to one of the isolated monoclonal antibodies. Mice with high levels of preexisting S2 cross-reactive antibodies mounted higher S protein specific binding antibodies, especially against S2, after being immunized with a SARS-CoV-2 S DNA vaccine. Similarly, we found that levels of preexisting S2 and P144-specific antibodies correlated positively with RBD binding antibody titers after two doses of inactivated SARS-CoV-2 vaccination in human. Collectively, our study revealed an alternative origin of preexisting S2-targeted antibodies and disclosed a previously neglected aspect of the impact of gut microbiota on host anti-SARS-CoV-2 immunity. |
| format | Article |
| id | doaj-art-cfda007d165d495f8e99736f2cdbb664 |
| institution | OA Journals |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-cfda007d165d495f8e99736f2cdbb6642025-08-20T02:29:56ZengTaylor & Francis GroupGut Microbes1949-09761949-09842022-12-0114110.1080/19490976.2022.2117503Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunityLiqiu Jia0Shufeng Weng1Jing Wu2Xiangxiang Tian3Yifan Zhang4Xuyang Wang5Jing Wang6Dongmei Yan7Wanhai Wang8Fang Fang9Zhaoqin Zhu10Chao Qiu11Wenhong Zhang12Ying Xu13Yanmin Wan14Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaShanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaShanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaShanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Immunology, School of Basic Medical, Jiamusi University, Jiamusi, ChinaClinical Laboratory, the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, ChinaShanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaShanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaInstitutes of Biomedical Sciences & Shanghai Key Laboratory of Medical Epigenetics, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaThe origins of preexisting SARS-CoV-2 cross-reactive antibodies and their potential impacts on vaccine efficacy have not been fully clarified. In this study, we demonstrated that S2 was the prevailing target of the preexisting S protein cross-reactive antibodies in both healthy human and SPF mice. A dominant antibody epitope was identified on the connector domain of S2 (1147-SFKEELDKYFKNHT-1160, P144), which could be recognized by preexisting antibodies in both human and mouse. Through metagenomic sequencing and fecal bacteria transplant, we demonstrated that the generation of S2 cross-reactive antibodies was associated with commensal gut bacteria. Furthermore, six P144 reactive monoclonal antibodies were isolated from naïve SPF mice and were proven to cross-react with commensal gut bacteria collected from both human and mouse. A variety of cross-reactive microbial proteins were identified using LC-MS, of which E. coli derived HSP60 and HSP70 proteins were confirmed to be able to bind to one of the isolated monoclonal antibodies. Mice with high levels of preexisting S2 cross-reactive antibodies mounted higher S protein specific binding antibodies, especially against S2, after being immunized with a SARS-CoV-2 S DNA vaccine. Similarly, we found that levels of preexisting S2 and P144-specific antibodies correlated positively with RBD binding antibody titers after two doses of inactivated SARS-CoV-2 vaccination in human. Collectively, our study revealed an alternative origin of preexisting S2-targeted antibodies and disclosed a previously neglected aspect of the impact of gut microbiota on host anti-SARS-CoV-2 immunity.https://www.tandfonline.com/doi/10.1080/19490976.2022.2117503Cross-reactive antibodySARS-CoV-2spike proteincommensal gut bacteriavaccine immunogenicity |
| spellingShingle | Liqiu Jia Shufeng Weng Jing Wu Xiangxiang Tian Yifan Zhang Xuyang Wang Jing Wang Dongmei Yan Wanhai Wang Fang Fang Zhaoqin Zhu Chao Qiu Wenhong Zhang Ying Xu Yanmin Wan Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity Gut Microbes Cross-reactive antibody SARS-CoV-2 spike protein commensal gut bacteria vaccine immunogenicity |
| title | Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity |
| title_full | Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity |
| title_fullStr | Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity |
| title_full_unstemmed | Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity |
| title_short | Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity |
| title_sort | preexisting antibodies targeting sars cov 2 s2 cross react with commensal gut bacteria and impact covid 19 vaccine induced immunity |
| topic | Cross-reactive antibody SARS-CoV-2 spike protein commensal gut bacteria vaccine immunogenicity |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2022.2117503 |
| work_keys_str_mv | AT liqiujia preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT shufengweng preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT jingwu preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT xiangxiangtian preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT yifanzhang preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT xuyangwang preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT jingwang preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT dongmeiyan preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT wanhaiwang preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT fangfang preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT zhaoqinzhu preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT chaoqiu preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT wenhongzhang preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT yingxu preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity AT yanminwan preexistingantibodiestargetingsarscov2s2crossreactwithcommensalgutbacteriaandimpactcovid19vaccineinducedimmunity |